Navigation Links
Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
Date:11/14/2011

has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule wholly-owned by Nektar, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel proprietary topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development stage products that leverage Nektar's proprietary technology platform include peginesatide, for which Affymax and partner Takeda submitted an NDA to the FDA in May 2011, and Baxter's BAX 855, a long-acting PEGylated rFVIII program planned to enter Phase 1 clinical development in 2011.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
2. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
5. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
6. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
8. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
9. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Legendary actor and director Danny ... PBAFacts campaign designed to educate and encourage patients with ... Pseudobulbar Affect (PBA) and to speak with their physician. ... has the ability to cry and laugh on cue ... experienced by people living with PBA episodes. ...
(Date:5/1/2015)... , May 1, 2015 Semler Scientific, Inc. ... company that develops, manufactures and markets products that assist ... today reported financial results for the first quarter ended ... quarter of 2015, Semler reported continued progress with year ... quarter revenue growth of 14%," said Doug Murphy-Chutorian ...
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... the American Diabetes ... Association 68th Scientific Sessions, SAN FRANCISCO, June 7 ... today at the American Diabetes,Association (ADA) 68th Scientific Sessions by ... shown to be a highly,selective inhibitor of dipeptidyl peptidase-4 (DPP-4), ...
... SAN FRANCISCO, California, June 6 , - ... results from the world,s largest ever study of ... using modified release,gliclazide and other drugs as required, ... particular, intensive treatment reduces,the risk of kidney disease ...
Cached Medicine Technology:Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies 2Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies 3Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies 4The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:5/1/2015)... May 01, 2015 Royal River Natural ... Maine, reports on a new study that found two ... swelling and improved physical function as well as standard ... osteoarthritis of the knee. , The report is part ... for Well Being® ,” which Royal River Natural Foods ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in both ... for telemedicine. , “Such action is unprecedented in ... said Jonathan Linkous, CEO of the American Telemedicine Association (ATA). ... embrace the use of telecommunications in the delivery of care. ... to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... The fields of genetics and genomics, ... of genes with one another and the environment, is ... , LabRoots, the premier producer of interactive virtual events ... host its annual conference spotlighting the recent advances in ... and Genomics 2015 , a two-day event presented entirely ...
(Date:5/1/2015)... 01, 2015 As the sale of ... 18-month anniversary, many people in the industry are looking ... According the latest annual report by the ArcView ... in 2014, and reached nearly $3 billion in combined ... affair with cannabis, combined with the ongoing economic recovery, ...
(Date:5/1/2015)... VA (PRWEB) May 01, 2015 On May ... Mexican celebration of Cinco de Mayo with a twist. ... of two 12 ounce or one 24 ounce frozen yogurt ... de Mayo celebration originated in 1862 in commemoration of a ... in Mexico and the United States, but events are also ...
Breaking Medicine News(10 mins):Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3Health News:sweetFrog to Celebrate Cinco de Mayo with a Yogurt Twist 2
... Rebuilding Revenue Base While Stabilizing Costs--, TSX ... - Vancouver, BC, Canada - Neovasc Inc. (TSXV: NVC), today ... 2009. , "The first quarter continued to show financial effects ... on our most promising growth areas," said Alexei Marko, chief ...
... for Recently Introduced MicroRNA-based Diagnostics Also Unveiled , ... a specialty pharmaceutical and diagnostic company, presented an overview ... American Society of Clinical Oncology (ASCO) Annual Meeting in ... of Receptor Tyrosine Kinases (RTK) Activation in Circulating Tumor ...
... PITTSBURGH, June 1 Since one child in 20 will have ... many young people will experience a Father,s Day without dad on ... to help ease the pain at this time, the Highmark Caring ... programs and services as well as online tools at no cost. ...
... A panoramic downtown Milwaukee view, lush greenery ... rooftop healing garden at Aurora St. Luke,s Medical ... awaiting guests at the newly opened Vince Lombardi ... Morland Hamilton Healing Conservatory. , , (Logo: ...
... ... based on scientific evidence, not marketing muscle or claims. CX3, Max Muscle Sports ... , ... (PRWEB) June 1, 2009 -- Creatine is perhaps one of the most widely used ...
... Contact an SSDI representation ... for initial applications will jump by 20 percent this year , ... Belleville, IL (Vocus) June 1, 2009 -- The Social Security Disability Insurance ... the next couple of years. This will make it even more important for people to find ...
Cached Medicine News:Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 2Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 3Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 5Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 6Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 7Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 8Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 9Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 10Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 11Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Easing the Pain of Father's Day Without Dad, Highmark Caring Place Helps Children Cope With the Death of a Parent 2Health News:Easing the Pain of Father's Day Without Dad, Highmark Caring Place Helps Children Cope With the Death of a Parent 3Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 2Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 3Health News:Max Muscle Sports Nutrition Releases The Truth About Creatine 2Health News:Max Muscle Sports Nutrition Releases The Truth About Creatine 3Health News:Max Muscle Sports Nutrition Releases The Truth About Creatine 4Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 2Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 3Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 4Health News:Social Security Disability Backlog Worsens, So Make Sure You Qualify Before You Apply 5
...
...
...
... employs titanium alloy plasma spray porous ... surface. Biomet's ArCom processed polyethylene is ... bearing material. The Maxim Knee System's ... tibial components offer excellent sizing options ...
Medicine Products: